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Drug-induced hypersensitivity syndrome (DIHS)/
drug reaction with eosinophilia and systemic
symptoms (DRESS) is a severe adverse systemic
reaction.1 DIHS is characterized by its limited
number of causative drugs, late onset, clinical
similarity to infectious mononucleosislike syndrome,
and prolonged clinical course owing to relapse.2
Subjects with DIHS are known to show reactivation
of human herpesvirus (HHV)-6, cytomegalovirus
(CMV), Epstein-Barr virus, and HHV-7.3 This report
describes the case of DIHS with a dramatic reactiva-
tion of CMV and a development of gastric ulcers, in
which CMV was immunohistochemically detected.CASE REPORT
A 78-year-old Japanese man presented with a
fever of 398C; pruritic erythematous rash over the
entire body; and marked swelling, erosions, and
crusts on the lips (Fig 1, A). In addition, purpura was
observed on the legs (Fig 1, B); no ocular involve-
ment was noted. Lymphadenopathy was observed in
the bilateral cervical and axillary lymph nodes. The
patient recently started carbamazepine for epilepsy.
He developed a high fever 2 weeks after starting and
a skin rash on his trunk and extremities 1 month after
starting. Blood test findings showed a leukocyte
count of 20,570 (normal range, 4,320-9,420) with
21.0% atypical lymphocytes and 3.5% eosinophils.
Furthermore, marked elevated levels of aspartate
aminotransferase (151 IU/L; normal range, 13-33 IU/
L), alanine aminotransferase (322 IU/L; 6-27 IU/L),
g-glutamyltransferase (1369 IU/L; 10-47 IU/L),
lactate dehydrogenase (571 U/L; 115-359 U/L), total
bilirubin (4.8 mg/dL; 0.2-1.3 mg/dL), and C-reactivethe Department of Dermatology, Graduate School of Med-
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pan. E-mail: tmakino@med.u-toyama.ac.jp.protein (7.89 mg/dL;\0.29 mg/dL) were detected. A
drug lymphocyte stimulation test was performed on
the 20th hospital day, with a positive result for
carbamazepine (202%; normal index, \179%). In
addition, a histologic examination of a skin lesion on
the abdomen found liquefaction degeneration in the
epidermis in addition to lymphocyte infiltration in
the epidermis and papillary dermis (Fig 1, C ). Based
on these findings, we tentatively diagnosed the skin
lesion as DIHS and administered prednisolone (PSL)
at a dose of 60 mg/d. Treatment with sulfamethox-
azole/trimethoprim was also initiated to prevent
Pneumocystis carinii infection. The patient’s tem-
perature immediately decreased, and the skin lesions
and liver dysfunction gradually improved. The
serum HHV-6 IgG titer was 1:20 on the first hospital
day and subsequently increased to 1:640 on the 30th
hospital day. The proportion of CMV-specific anti-
genemia (C7-HRP)epositive cells was 11/50,000 of
white blood cells (WBCs) on the 15th hospital days
and then increased to 1,354/50,000WBCs on the 30th
hospital day. Therefore, ganciclovir treatment was
started on the 30th hospital day. However, the
patient suddenly had hematemesis on the 38th
hospital day. At that time, the dose of PSL was
tapered to 30 mg/d, and no skin lesions developed.
An emergency endoscopic examination foundJAAD Case Reports 2015;1:215-8.
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Fig 1. Clinical and histopathologic findings. A, Erythematous rash on the entire body. B,
Purpura on the bilateral legs. C, Liquefaction degeneration in the epidermis and lymphocyte
infiltration in the epidermis and papillary dermis. D, A punched-out ulcer (arrowhead ) in the
gastric wall. E, An intracellular inclusion body (arrowhead ) in the pyloric gland. F, The
detection of CMV antigens (arrows) around the fundic glands. (C and E, Hematoxylin-eosin
stain.)
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although the patient exhibited no clinical symptoms
of gastric ulcers upon admission. Furthermore,
intracellular inclusion bodies were histologically
observed in the pyloric glands (Fig 1, E ), and an
immunohistochemical examination found CMV an-
tigens around the fundic glands (Fig 1, F ). These
findings suggested a CMV-associated gastric ulcer.
The gastric ulcer improved after treatment with a
proton pump inhibitor and ganciclovir, and the
number of C7-HRPepositive cells decreased to 1/
50,000 WBCs on the 40th hospital day. However, the
patient died thereafter of respiratory failure causedby pneumocystis carinii pneumonia on the 64th
hospital day despite being on prophylaxis with
sulfamethoxazole/trimethoprim. His clinical course
is shown in Fig 2.
DISCUSSION
The following criteria for the diagnosis of DIHS/
DRESS have been proposed by the Japanese
consensus group: 1) morbilliform eruption devel-
oping greater than 3 weeks after starting therapy
with a limited number of drugs, 2) lymphade-
nopathy, 3) a fever ([388C), 4) leukocytosis
([10 3 109/L), atypical lymphocytosis ([5%) or
Fig 2. Clinical course of the patient. ALT, alanine transaminase; AST, aspartate aminotrans-
ferase; GTP, guanosine-59-triphosphate; LDH, lactate dehydrogenase.
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transaminase[100U/L), and 6) HHV-6 reactivation.
The diagnosis requires the presence of 5 of the
6 criteria including HHV-6 reactivation.4 CMV
reactivation can cause serious symptoms in immu-
nocompromised subjects, such as organ transplant
recipients and those receiving immunosuppressive
agents.5 The reactivation of CMV is also experi-
enced by severe DIHS patients, and it has been
previously reported in approximately 30% of DIHS
patients.6 A patient with CMV reactivation clinically
has recurring transient fever, cutaneous eruptions,
or various severe complications. In particular,
gastrointestinal bleeding, myocarditis, and pneu-
monia may occasionally be fatal in DIHS patients.
Asano et al7 previously reported the case of 2 DIHS
patients with CMV reactivation who had gastroin-
testinal hemorrhage and red papules with erosions
on the trunk and CMV antigens in tissue specimens
obtained from the skin lesions.7 In this case, the
number of C7-HRPepositive cells drastically
increased during the period between the 15th and
30th hospital days, and CMVantigens were detected
in the tissue specimen of the gastric ulcer; therefore,
we speculate that marked CMV reactivation may
have occurred in this patient and that immunosup-
pression caused by treatment with high-dose PSL
may have exacerbated this situation. CMV is rarely
observed in cases of gastric ulcers in immunocom-
promised patients8,9; however, to our knowledge,
there are no previous reports of the detection
of CMV antigens in the gastric mucosa of patients
with DIHS.
Elderly and male DIHS patients, similar to this
patient, are reported to have increased risk of CMV
disease.7 In the event of no response to oral steroids,pulsed intravenous high-dose corticosteroid therapy
during the acute stage is considered a therapeutic
option for DIHS patients, although the degree and
duration of HHV-6 and CMV reactivation may be
enhanced.10 In addition, a rapid reduction in the
WBC count during the clinical course may be a
useful predictor of the development of CMV
disease. Gastrointestinal bleeding caused by CMV is
unpredictable and often takes a rapidly fatal
course; therefore, early recognition of CMV reactiva-
tion is required for proper management in DIHS
patients, and the prompt administration of anti-CMV
treatment may prevent DIHS patients from having
serious symptoms from CMV infection.REFERENCES
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